A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
|Videos|July 11, 2019
Video: Adult anxiety, depression linked with atopic dermatitis
Author(s)Bobby Lazzara, M.D.
Advertisement
Published in the British Journal of Dermatology, a cross sectional population-based study of almost 3,000 individuals looking at anxiety and depression in adults with atopic dermatitis found that adults with atopic dermatitis had significantly higher self-reported anxiety and depression scores compared with adults without atopic dermatitis.
The take home message: It’s easy to ascertain why self confidence and social interactions are impaired and may linger, even after treatment begins in patients with atopic dermatitis. Remember you are just not treating the skin, you’re treating the whole patient.
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5